Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19
-
Published:2023-08-03
Issue:8
Volume:13
Page:786
-
ISSN:2079-6374
-
Container-title:Biosensors
-
language:en
-
Short-container-title:Biosensors
Author:
Mousavi Seyyed Mojtaba1, Kalashgrani Masoomeh Yari2, Gholami Ahmad2ORCID, Omidifar Navid3, Binazadeh Mojtaba4ORCID, Chiang Wei-Hung1ORCID
Affiliation:
1. Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan 2. Biotechnology Research Center, Shiraz University of Medical Science, Shiraz 71468-64685, Iran 3. Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran 4. Department of Chemical Engineering, School of Chemical and Petroleum Engineering, Shiraz University, Shiraz 71557-13876, Iran
Abstract
The COVID-19 pandemic has spurred demand for efficient and rapid diagnostic tools that can be deployed at point of care to quickly identify infected individuals. Existing detection methods are time consuming and they lack sensitivity. Point-of-care testing (POCT) has emerged as a promising alternative due to its user-friendliness, rapidity, and high specificity and sensitivity. Such tests can be conveniently conducted at the patient’s bedside. Immunodiagnostic methods that offer the rapid identification of positive cases are urgently required. Quantum dots (QDs), known for their multimodal properties, have shown potential in terms of combating or inhibiting the COVID-19 virus. When coupled with specific antibodies, QDs enable the highly sensitive detection of viral antigens in patient samples. Conventional lateral flow immunoassays (LFAs) have been widely used for diagnostic testing due to their simplicity, low cost, and portability. However, they often lack the sensitivity required to accurately detect low viral loads. Quantum dot (QD)-based lateral flow immunoassays have emerged as a promising alternative, offering significant advancements in sensitivity and specificity. Moreover, the lateral flow immunoassay (LFIA) method, which fulfils POCT standards, has gained popularity in diagnosing COVID-19. This review focuses on recent advancements in QD-based LFIA for rapid POCT COVID-19 diagnosis. Strategies to enhance sensitivity using QDs are explored, and the underlying principles of LFIA are elucidated. The benefits of using the QD-based LFIA as a POCT method are highlighted, and its published performance in COVID-19 diagnostics is examined. Overall, the integration of quantum dots with LFIA holds immense promise in terms of revolutionizing COVID-19 detection, treatment, and prevention, offering a convenient and effective approach to combat the pandemic.
Funder
Ministry of Science and Technology, Taiwan
Subject
Clinical Biochemistry,General Medicine,Analytical Chemistry,Biotechnology,Instrumentation,Biomedical Engineering,Engineering (miscellaneous)
Reference181 articles.
1. WHO (2005). Statement on the Second Meeting of the International Health Regulations Emergency Committee regarding the Outbreak of Novel Coronavirus (2019-nCoV), WHO. 2. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N. Engl. J. Med.,2020 3. Mousavi, S.M., Hashemi, S.A., Rahmanian, V., Kalashgrani, M.Y., Gholami, A., Omidifar, N., and Chiang, W.-H. (2022). Highly sensitive flexible SERS-based sensing platform for detection of COVID-19. Biosensors, 12. 4. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR;Corman;Eurosurveillance,2020 5. Quantification using real-time PCR technology: Applications and limitations;Klein;Trends Mol. Med.,2002
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|